Location Directory

Clinical trials in Columbus, Ohio

This page shows live ClinicalTrials.gov search results for Columbus, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10863

Shown on this page

Current sort

Institutions in Columbus

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Ohio State University Wexner Medical Center

Live official records

Open in full search

Conditions: Acute Migraine
Interventions: Elismetrep; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 113
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 93 more

Conditions: Hypertriglyceridemia, Severe Hypertriglyceridemia
Interventions: ION775; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Lincoln, California • Aurora, Colorado • Boca Raton, Florida + 13 more

Conditions: Neoplasms
Interventions: Gene-modified (GM) T cell therapy; Genetic
Lead sponsor: Celgene; Industry
Eligibility: Not listed
Enrollment: 1,541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2043
U.S. locations: 104
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more

Conditions: Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
Interventions: Barzolvolimab, Matching Placebo; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 22 more

Conditions: Primary Generalized Tonic-Clonic Seizures
Interventions: XEN1101, Placebo; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 62
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more

Conditions: Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
Interventions: furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy; Drug
Lead sponsor: ArriVent BioPharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 69
States / cities: Daphne, Alabama • Yuma, Arizona • Fayetteville, Arkansas + 64 more

Conditions: Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Interventions: The Supira System, Impella; Device
Lead sponsor: Supira Medical; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Loma Linda, California • Sacramento, California • Thousand Oaks, California + 21 more

Conditions: Antibody-mediated Rejection, Microvascular Inflammation
Interventions: Felzartamab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Rochester, Minnesota + 9 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Capecitabine, Carboplatin, Cisplatin; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 1023
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more

Conditions: Tumours, Gynecological
Interventions: Mo-Rez, Dostarlimab, Bevacizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: La Jolla, California • Aurora, Colorado • Rochester, New York + 2 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin, Cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 47
States / cities: Beverly Hills, California • La Jolla, California • Los Alamitos, California + 40 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 47
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Concord, California + 41 more

Clinical trials in Columbus, Ohio

Filter and sort this location

Institutions in Columbus

Live official records

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

A Study to Assess the Safety, Tolerability and Efficacy of ION775

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes